Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 52, Issue 9, 2013, Pages 1556-1562

  Nijjar, Jagtar Singh ^a   Tindell, Alistair ^a   Mcinnes, Iain B ^a   Siebert, Stefan ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Biologic non responder; DMARD; Fostamatinib; Kinase; Methotrexate; R406; R788; Rheumatoid arthritis; Spleen tyrosine kinase

Indexed keywords

FOSTAMATINIB; IMATINIB; METHOTREXATE; PROTEIN KINASE SYK;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ANEMIA; ARTICLE; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DYSPEPSIA; EDEMA; ENZYME INHIBITION; FATIGUE; GASTRITIS; HEADACHE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; INNATE IMMUNITY; NAUSEA; NEUTROPENIA; PATHOGENESIS; PLACEBO EFFECT; PRIORITY JOURNAL; RASH; REMISSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

BIOLOGIC NON-RESPONDER; DMARD; FOSTAMATINIB; KINASE; METHOTREXATE; R406; R788; RHEUMATOID ARTHRITIS; SPLEEN TYROSINE KINASE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ENZYME INHIBITORS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OXAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; TREATMENT OUTCOME;

EID: 84879817002     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket225     Document Type: Article

References (27)

1. O'Hare T, Zabriskie MS, Eiring AM et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 201212:513-26.
2. Manning G, Whyte DB, Martinez R et al. The protein kinase complement of the human genome. Science 2002298: 1912-34.
3. O'Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003348:994-1004.
4. Lugo TG, Pendergast AM, Muller AJ et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990247:1079-82.
5. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 19962:561-6.
6. Schindler T, Bornmann W, Pellicena P et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000289:1938-42.
7. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006355:2408-17.
8. Kantarjian HM, Talpaz M, Giles F et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006145:913-23.
9. Saglio G, Kim D-W, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010362:2251-9.
10. Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010362:2260-70.
11. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012367:508-19.
12. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012367:495-507.
13. Mócsai A, Ruland J, Tybulewicz VLJ. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 201010:387-402.
14. Cha H-S, Boyle DL, Inoue T et al. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006317:571-8.
15. Pine PR, Chang B, Schoettler N et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007124:244-57.
16. Coffey G, DeGuzman F, Inagaki M et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 2012340:350-9.
17. Ozaki N, Suzuki S, Ishida M et al. Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibodyinduced arthritis. Int Immunol 201224:539-50.
18. Weinblatt ME, Kavanaugh A, Burgos-Vargas R et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 200858:3309-18.
19. Weinblatt ME, Kavanaugh A, Genovese MC et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010363:1303-12.
20. Genovese MC, Kavanaugh A, Weinblatt ME et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 201163:337-45.
21. Grossbard E, Baluom M, Kivitz A. A phase I randomized, double-blind, placebo-controlled, pharmacokinetic study of R788/406 and methotrexate in sixteen patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2006; 54(Suppl 9):S408.
22. Otón T, Silva-Fernández L, Andreu JL. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2011364:83; author reply 84.
23. Boers M. Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations. Arthritis Rheum 201163:329-30.
24. Kavanaugh A, Weinblatt M, Genovese M et al. Longerterm safety of fostamatinib (R788) in patients with rheumatoid arthritis analysis of clinical trial data from up to 2 years of exposure [abstract]. Arthritis Rheum 2011; 63(Suppl 10):2594.
25. Okamoto H, Kobayashi A. Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2011364: 83-4; author reply 84.
26. Kazerounian S, Duquette M, Reyes MA et al. Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood 2011117:4658-66.
27. Banna GL, Collovà E, Gebbia V et al. Anticancer oral therapy: emerging related issues. Cancer Treat Rev 201036: 595-605.